Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats

被引:60
作者
Hammerbeck, David M.
Burleson, Gary R.
Schuller, Craig J.
Vasilakos, John P.
Tomai, Mark
Egging, Elaine
Cochran, Felicia R.
Woulfe, Susan
Miller, Richard L.
机构
[1] 3M Pharmaceut, Dept Pharmacol, M Ctr 3, St Paul, MN 55144 USA
[2] Burleson Res Technol Inc, Morrisville, NC 27560 USA
关键词
toll-like receptor; influenza; innate immunity; interferon; cytokine;
D O I
10.1016/j.antiviral.2006.07.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Toll-like receptors (TLR) detect conserved molecular patterns expressed by pathogens. Detection of the "molecular signature" for RNA viruses including influenza has been attributed to TLR3, TLR7, and TLR8. In the present study, compound 3M-011 was shown to be a synthetic human TLR7/8 agonist and cytokine inducer. 3M-011 was investigated as a stand-alone immune response modifier in a rat model of human influenza. Intranasal (IN) administration of 3M-011 significantly inhibited H3N2 influenza viral replication in the nasal cavity when administered from 72 It before IN viral inoculation to 6 h after inoculation. Viral inhibition correlated with the ability of the TLR7/8 agonist to stimulate type I interferon (IFN) and other cytokines such as tumor necrosis factor-alpha, interleukin-12, and IFN-gamma from rat peripheral blood mononuclear cells. Prophylactic administration of TLR7/8 agonist also suppressed influenza viral titers in the lung, which corresponded with local IFN production. The activity of the TLR7/8 agonist resulted in greater inhibition of viral titers compared to rat recombinant IFN-alpha administered in a comparable dosing regimen. These studies indicate that TLR7/8 agonists may have prophylactic and therapeutic benefits in the treatment of respiratory viral infections, such as influenza. when administered prior to or shortly after viral inoculation. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 65 条
[21]   Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production [J].
Gerster, JF ;
Lindstrom, KJ ;
Miller, RL ;
Tomai, MA ;
Birmachu, W ;
Bomersine, SN ;
Gibson, HJ ;
Imbertson, LM ;
Jacobson, JR ;
Knafla, RT ;
Maye, PV ;
Nikolaides, N ;
Oneyemi, FY ;
Parkhurst, GJ ;
Pecore, SE ;
Reiter, MJ ;
Scribner, LS ;
Testerman, TL ;
Thompson, NJ ;
Wagner, TL ;
Weeks, CE ;
Andre, JD ;
Lagain, D ;
Bastard, Y ;
Lupu, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) :3481-3491
[22]   Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod [J].
Gibson, SJ ;
Lindh, JM ;
Riter, TR ;
Gleason, RM ;
Rogers, LM ;
Fuller, AE ;
Oesterich, JL ;
Gorden, KB ;
Qiu, XH ;
McKane, SW ;
Noelle, RJ ;
Miller, RL ;
Kedl, RM ;
Fitzgerald-Bocarsly, P ;
Tomai, MA ;
Vasilakos, JP .
CELLULAR IMMUNOLOGY, 2002, 218 (1-2) :74-86
[23]   Synthetic TLR Agonists reveal functional differences between human TLR7 and TLR8 [J].
Gorden, KB ;
Gorski, KS ;
Gibson, SJ ;
Kedl, RM ;
Kieper, WC ;
Qiu, XH ;
Tomai, MA ;
Alkan, SS ;
Vasilakos, JP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (03) :1259-1268
[24]   The interferon antiviral response: from viral invasion to evasion [J].
Grandvaux, N ;
tenOever, BR ;
Servant, MJ ;
Hiscott, J .
CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (03) :259-267
[25]   Viral and nonviral uses of imiquimod: A review [J].
Gupta, AK ;
Cherman, AM ;
Tyring, SK .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2004, 8 (05) :338-352
[26]   COMBINED ANTIVIRAL AND ANTIMEDIATOR TREATMENT OF RHINOVIRUS COLDS [J].
GWALTNEY, JM .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (04) :776-782
[27]  
Harper Scott A., 2005, Morbidity and Mortality Weekly Report, V54, P1
[28]   POSTTHERAPY SUPPRESSION OF GENITAL HERPES-SIMPLEX VIRUS (HSV) RECURRENCES AND ENHANCEMENT OF HSV-SPECIFIC T-CELL MEMORY BY IMIQUIMOD IN GUINEA-PIGS [J].
HARRISON, CJ ;
MILLER, RL ;
BERNSTEIN, DI .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :2059-2064
[29]   MODIFICATION OF IMMUNOLOGICAL RESPONSES AND CLINICAL-DISEASE DURING TOPICAL R-837 TREATMENT OF GENITAL HSV-2 INFECTION [J].
HARRISON, CJ ;
JENSKI, L ;
VOYCHEHOVSKI, T ;
BERNSTEIN, DI .
ANTIVIRAL RESEARCH, 1988, 10 (4-5) :209-223
[30]   Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator [J].
Hayashi, M ;
Satou, E ;
Ueki, R ;
Yano, M ;
Miyano-Kurosaki, N ;
Fujii, M ;
Takaku, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (01) :230-236